Kisqali 200 mg (Tablet)
Unit Price: ৳ 3,200.00 (3 x 21: ৳ 201,600.00)
Strip Price: ৳ 67,200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ribociclib |
| Company | Novartis bangladesh ltd |
Indications
- Indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer
- Can be used in combination with aromatase inhibitor or fulvestrant
Pharmacology
- Inhibitor of cyclin-dependent kinase (CDK) 4 and 6
- Regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb)
- Decreases cell proliferation in breast cancer cell lines
- Inhibits pRb phosphorylation and reduces tumor volumes
Dosage & Administration
- Oral administration with or without food
- Recommended starting dose: 600 mg orally once daily for 21 days followed by 7 days off treatment
Interaction
- Avoid concomitant use with strong CYP3A inhibitors
- May require dose reduction when given with sensitive CYP3A substrates
- Avoid concomitant use with drugs known to prolong QT interval
Side Effects
- Common adverse reactions include leukocytes, hemoglobin, and platelets decreased, nausea, fatigue, and diarrhea
Pregnancy & Lactation
- Can cause fetal harm when administered to a pregnant woman
- Unknown if present in human milk
Precautions & Warnings
- Monitor for pulmonary symptoms indicative of ILD/pneumonitis
- Severe cutaneous adverse reactions can occur
- Monitor for QT interval prolongation and hepatobiliary toxicity
- Perform complete blood count before initiating therapy
- Potential risk to a fetus, advise use of effective contraception during therapy
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Keep below 30°C temperature
- Keep away from light & moisture
- Keep out of the reach of children